Roche Czech Republic made a net profit of CZK 252 mil in 2016, up 394% compared to the previous year. Historically, between 2003 and 2016, the company's net profit reached a high of CZK 252 mil in 2016 and a low of CZK 3.04 mil in 2003.
The result implies a return on equity of 19.2% and a return on invested capital of 12.8% in 2016. That is compared to an average of 9.34% and 6.60% over the last five years.
The company has been operating with average EBITDA margin of 6.07% in the last 5 years and an average net margin of 2.34%.
Since 2011, the firm's net profit increased by 399% or an average of 37.9% a year.
As far as Roche Czech Republic's peers are concerned, Pfizer Czech Republic generated ROE of 6.03% and ROCE of 5.37% in 2016. Bayer Czech Republic's profitability reached 57.6% and 23.1%, respectively. Amgen Czech Republic operated with 15.9% and 17.9% returns in 2016.
You can see all the company’s data at Roche Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
